ALKERMES | ALKS - Trade Debtors


ALKERMES reported $456.48M in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
AbbVie USD 12.48B 110M Mar/2026
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
ALKERMES USD 456.48M 48.85M Jun/2026
Amgen USD 10.23B 1.09B Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 23.48B 2.3B Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
J&J USD 22.54B 1.21B Mar/2026
Malin Corporation EUR 500K 300K Dec/2024
Merck USD 12.21B 435M Mar/2026
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Otsuka Holdings JPY 595.39B 58.02B Jun/2026
Ovoca Bio EUR 53K 14K Dec/2025
Pfizer USD 16.19B 19M Jun/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026